Grape King BioTPE:1707 -0.11%78 EBITDA Margin % is 31.47% as of Dec. 2025, which is 8% above its 10-year median of 29.21. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Grape King Bio ranks better than 83.37% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Grape King Bio's EBITDA for the
three
months ended in Dec. 2025 was NT$945 Mil. Grape King Bio's Revenue for the
three
months ended in Dec. 2025 was NT$3,002 Mil. Therefore, Grape King Bio's EBITDA margin for the quarter that ended in Dec. 2025 was 31.47%.
Grape King Bio (TPE:1707) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Grape King Bio EBITDA Margin % Related Terms
Grape King Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Grape King Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a EBITDA Margin % of 31.47% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grape King Bio and its competitors. This is near median its historical median of 29.21. Over the past decade, Grape King Bio's EBITDA Margin % has ranged from 27.80 to 30.62. According to the industry distribution chart, Grape King Bio ranks #159 out of 956 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Grape King Bio's EBITDA Margin % too high?
Grape King Bio's current EBITDA Margin % of 31.47% is near median its 10-year median of 29.21. Over the past 10 years, this metric has ranged from a low of 27.80 to a high of 30.62. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Grape King Bio's value of 31.47% is 151.5% above this industry median. Based on the distribution chart, Grape King Bio ranks #159 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #159 out of 956 companies for EBITDA Margin %. This places Grape King Bio in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Grape King Bio's value of 31.47% is 151.5% above this benchmark. Historically, Grape King Bio's own EBITDA Margin % has ranged from 27.80 to 30.62 over the past decade. While the company's 10-year median is 29.21 vs. the industry median of 12.52, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current EBITDA Margin % of 31.47% is 151.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current EBITDA Margin % is 31.47%, which is near median its own 10-year median of 29.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current EBITDA Margin % is 31.47%, which is near median its 10-year median of 29.21 and 151.5% above the Drug Manufacturers industry median of 12.52. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current EBITDA Margin % is 31.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
EBITDA Margin %: 31.47% (near median its 10-year median of 29.21)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 151.5% above the Drug Manufacturers median (#159 of 956)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
